Rilzabrutinib Patent Expiration
Rilzabrutinib was first introduced by Genzyme Corp
Rilzabrutinib Patents
Given below is the list of patents protecting Rilzabrutinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Wayrilz | US11708370 | Solid Forms Of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxyphenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile | Feb 20, 2041 | Genzyme Corp |
| Wayrilz | US12178818 | Methods For Treating Immune Thrombocytopenia By Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile | Oct 13, 2040 | Genzyme Corp |
| Wayrilz | US8940744 | Pyrazolopyrimidine Compounds As Kinase Inhibitors | Sep 06, 2033 | Genzyme Corp |
| Wayrilz | US9266895 | Substituted Pyrazolo[3,4-D]Pyrimidines As Kinase Inhibitors | Sep 06, 2033 | Genzyme Corp |
| Wayrilz | US9994576 | Substituted Pyrazolo[3,4-D]Pyrimidines As Kinase Inhibitors | Sep 06, 2033 | Genzyme Corp |
| Wayrilz | US9580427 | Kinase Inhibitors | Mar 01, 2033 | Genzyme Corp |
Rilzabrutinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Rilzabrutinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
